Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA6 | P23280 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | CA5A | P35218 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL801824 | 0.90 | LMNA (0.62) | LMNAMEN1KMT2ARXFP1CYP3A4 | |
| SCHEMBL290542 | 0.82 | LMNA (0.69) | LMNAMEN1KMT2ACYP3A4TSHR | |
| Acetosyringone SCHEMBL15511 | 0.82 | LMNA (1.00) | LMNAMEN1KMT2ACYP3A4CA12 | |
| SCHEMBL10824650 | 0.82 | MEN1 (0.58) | LMNAMEN1KMT2ARXFP1CYP3A4 | |
| SCHEMBL668540 | 0.82 | CA12 (0.69) | LMNAMEN1KMT2ARXFP1CYP3A4 | |
| SCHEMBL2114318 | 0.80 | KMT2A (0.61) | LMNAMEN1KMT2ARXFP1CYP3A4 | |
| SCHEMBL1004561 | 0.80 | TSHR (0.59) | LMNAMEN1KMT2ARXFP1CYP3A4 | |
| SCHEMBL5240901 | 0.80 | MEN1 (0.56) | LMNAMEN1KMT2ARXFP1CYP3A4 | |
| SCHEMBL668639 | 0.80 | RXFP1 (0.56) | LMNAMEN1KMT2ARXFP1CYP3A4 | |
| SCHEMBL24488761 | 0.80 | LMNA (0.67) | LMNAMEN1KMT2ACYP3A4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025078808-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| US-20250122212-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| US-20160025900-A1 | ORGANIC ELECTROLUMINESCENT DISPLAY DEVICE AND METHOD FOR MANUFACTURING SAME | Konica Minolta, Inc. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160025900-A1 | ORGANIC ELECTROLUMINESCENT DISPLAY DEVICE AND METHOD FOR MANUFACTURING SAME | Konica Minolta, Inc. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8288560-B2 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2012-10-16 | — | — | US | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | IPSEN PHARMA S.A.S. (FR) | 2011-07-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | OXER1, OPRL1, CHRNA7 | LMNA 4025/4885MEN1 4280/4885KMT2A 3849/4885 |
| US-20250122212-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | LMNA 3312/4885MEN1 617/4885KMT2A 4453/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | LMNA 1852/4885MEN1 2532/4885KMT2A 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.